Search

Studies of the effects of luliberin (luteinizing hormone-releasing hormone) on cardiac cells showed that the hormone is specifically bound by the sarcolemmal membrane. The activity of the membrane enzyme -- reception of luliberin involves two types of binding sites with high (K' = 10(7) M-1) and low (K'' = 10(5) M-1) affinities for the hormone, respectively. The hormone has no effect on the activities of adenylate cyclase and phosphodiesterase.

The rate of degradation of intracellular proteins at different growth stages of Saccharomyces cerevisiae yeast was determined. It has been demonstrated that the rate of degradation of intracellular proteins increases 2--3-fold at the late exponential phase. The increase was accompanied by corresponding changes in the activities of yeast proteinases A and B. In the presence of specific yeast proteinase inhibitors (pepstatin and phenylmethylsulfonyl fluoride) the rate of protein degradation in vivo decreased. The intermediate products of cell protein degradation have been found. These TCA-insoluble products could be extracted by various solvent systems. Their subsequent brakdown was suppressed by specific proteinase inhibitors.

The authors elaborated two variants of the radioimmunochemical method of determination of the LH-releasing factor (LH-RF). Diluted antisera (AS) obtained by the immunization of rabbits with the LH-RF-ovalbumin were used in the first method; AS polymerized with isobutyl ester of chlorcarbonic acid were used in the second one. The minimal amount of the hormone determined in the I variant was 5 pg, and in the 11 one--20 to 30 pg. The method is highly specific, since the antisera gave no cross reaction with a wide set of protein-peptide hormones synthesized with the hypothalamus and the hypophysis. The presence in the samples of tissue components of the hypothalamus and of the cerebral cortex extractable with 2M CH3COOH failed to influence the precision of the test. In examining the LH-RF content in the brain structures there was revealed that in the sexually mature male rats the whole hypothalamus contained an average of 7.5 ng, the arcuate nuclei--1.5 ng and the medial eminence--2.5 ng of LH-RF; the supraoptic nuclei and the cerebral cortex contained no LH-RF determinable by the method described. Two weeks after the castration the mean content of the hormone in the whole hypothalamus decreased to 5.5 ng, in the medial eminence--to 0.6 ng, and showed no significant change in the arcuate nuclei.

The binding of labelled naloxone, morphine and (D-Ala2,D-Leu5)enkephalin (DADL) to oocyte membranes of the toad Bufo viridis was investigated. The opiate antagonist naloxone binds to the membranes much more effectively than morphine or DADL. The binding of [3H]naloxone is reversible and saturating. The bound [3H]naloxone is readily replaced by unlabelled naloxone or bremazocine (kappa-agonist), far less effectively by morphine (mu-agonist) and SKF 10.047 (sigma-agonist) and is not practically replaced by DADL (delta-agonist), beta-endorphin (epsilon-agonist) and other neuropeptides. Analysis of experimental results in Scatchard plots revealed two types of binding sites with a high (Kd = 15 nM) and low (Kd = 10(3) nM) affinity for naloxone. The number of sites responsible for the binding of naloxone possessing a high affinity is 16 pmol-/mg of oocyte homogenate protein, i.e., 20-50 times as great as in the toad or rat brain. Trypsin and p-chloromercurybenzoate decrease the binding of [3H]naloxone. The oocyte extract is capable of replacing the membrane-bound [3H]naloxone, on the one hand, and of inhibiting the smooth muscle contracture of the rabbit vas deferens, on the other. This inhibition is reversed by naloxone and can also be induced by bremazocine, but not by morphine, DADL and SKF 10.047. In all probability oocytes contain compounds that are similar to opiate kappa-agonists. It may also be possible that these compounds mediate their effects via specific receptors and are involved in the control over maturation of oocytes and early development of toad eggs.

Luliberin, a luteinizing hormone-releasing hormone, was shown to inhibit the respiratory enzymes of rat liver mitochondria and submitochondrial particles prepared from beef heart mitochondria. At the hormone concentration of 8.10(-6) M the NADH-oxidase activity of the submitochondrial particles was inhibited by 50%. The fragments of the hormone and its analogs and pyroglutamic acid, oxytocin and bradikinin possessed practically no inhibiting effects. In the case of submitochondrial particles the inhibition was only observed in the presence of Ca2+ and was significantly decreased after addition of bovine serum albumin and phospholipase inhibitors -- butacaine and dicaine. It is assumed that the effect of luliberin on the respiratory chain is mediated through mitochondrial phospholipase.

The distribution of luliberin (luteinizing hormone-releasing hormone, LH-RH) was studied. LH-RH-like factor showing analogous immunochemical and chromatographic properties was detected in the liver, kidneys, duodenum, pancreas, adrenal glands and heart of rats. The concentration of immunoreactive LH-RH in the liver, kidneys, duodenum, pancreas and adrenal glands was nearly equal (5 to 7 pg per mg of methanol extract obtained from acetic acid extract of acetone powder), its concentration in the heart being somewhat lower (2 pg per mg of extract). Only minute amounts of this factor were present in blood cells. Immunoreactive LH-RH found in visceral organs may be of hypothalamic origin or may be synthesized in these organs (in situ).

Degradation of [125I]-LH-RH by peptidases of hypothalamus, liver and heart of the rat and the effects of LH-RH, LH-RH antagonist D-Phe2-Phe3-D-Phe6-LH-RH, LH-RH5-10, oxytocin, bradikinin, thyrotrophin-releasing hormone, melanocyte-inhibiting factor, luteinizing, follicle-stimulating, lactogenic and growth hormones were studied. It was shown that the degradation was inhibited with maximal efficiency by non-labelled LH-RH (Ki = 1,7--2,0 . 10(-6) M). This observation is indicative of peptidase specificity for LH-RH. It is assumed that specific peptidases of liver and heart are involved in the reglation of LH-RH concentration in these organs.

Distribution of the activities of some mitochondrial enzymes after sucrose density gradient ultracentrifugation of cell homogenates of S. cerevisiae in the early and late exponential growth phases is studied. It is demonstrated that young yeast cells have a characteristic complex distribution of NADH oxidase (cyanide-sensitive), succinate:ferricyanide-oxidoreductase (or succinate:2,6-dichlorophenol indophenol-oxidoreductase), NADH:2,6-dichlorophenol indophenol-oxidoreductase and cytochrome oxidase activities in sucrose density gradient; the distribution patterns of these activities are different. All the above activities are detected in a single relatively narrow band in mature yeast cells. Similar results are obtained in the experiments with glucose or galactose as a carbon source in the yeast growth media. The Arrhenius plots for NADH oxidase (as well as for succinate:2,6-dichlorophenol indophenol-oxidoreductase) activity do not differ in the case of "light" and "heavy" mitochondrial structures characteristic of yeast cells in the early exponential growth phase. Nevertheless, "light" and "heavy" mitochondrial structures differ with respect of the arrangement of certain respiratory chain components in their membranes NADH-dehydrogenase and cytochrome oxidase). This conclusion is drawn from the results obtained in the study of the interaction of the two types of structures with Fe(CN)6(3-), a non-penetrating ion and the antiserum to yeast mitochondria.

Opioid mu-agonist morphine, delta-agonist D-Ala2,D-Leu5-enkephalin (DADL) and kappa-agonist bremazocine locally applied to the surface of turtle visual cortex inhibited the orthodromic evoked potential (EP; fast negative component N1). The lack of cross-desensitization to the inhibitory action of opioids upon EP indicates that the drugs exert their effects via different opioid receptors. Morphine and bremazocine predominantly inhibited the left cortex EP, whereas DADL was a potent inhibitor of the right cortex EP. Thus opioid receptors which modulate evoked electrical activity of the left visual cortex (LVC) apparently belong mostly to mu- and kappa-type while delta-receptors were predominantly responsible for the modulation of electrical activity in the right visual cortex (RVC). Application of LVC- and RVC-extracts to the cortex surface led to EP inhibition, which was partially (60-80%) prevented by antagonist naloxone. LVC-extract proved to be a more potent inhibitor of the left cortex EP, whereas RVC-extract was found to be more effective when applied to the right cortex. It is suggested that not only opioid receptors, but also their endogenous ligands are lateralized in turtle visual cortex.

The level of luliberin, the luteinizing hormone-releasing hormone (LH-RH), and the possibility of the hormonal control of metabolic and biosynthetic processes in the heart were studied. It was shown that the rat heart contains a factor, which is immunochemically and chromatographically related to LH-RH (19--46 picograms per organ). Intraperitoneal injection of LH-RH increases the activities of phosphorylase A and ornithine decarboxylase and the concentration of 3',5'-AMP and potentiates the stimulating effect of adrenaline on ornithine decarboxylase.

The opiate antagonist naloxone modifies the electric activity of some identified neurons of the Helix lucorum which have not been preliminary exposed to the effect of exogenous opioids. Some neurons are excited while others are inhibited by naloxone, and in both cases the reaction may have both a short and long latent period. The reactions depend on naloxone dose and become less expressed or are blocked when naloxone is administered together with the agonists of opiate receptor (morphine, D-Ala2, D-Leu5-enkephalin, bremazocine and beta-endorphin). Opioids alone do not produce any effect on neurons. The effect of naloxone on neurons is assumed to be a result of the elimination by the opiate antagonist of the tonic effect of endogenous opioids by their replacing on opiate receptors which are constantly stimulated by endogenous ligands.

The presence of immunoreactive LH-releasing hormone (LH-RH) was revealed in the epiphysis of rats by radioimmunochemical method. The content of this hormone displayed circadian variations: it was maximum at 6 p.m. and minimum at 6 a.m. Intravenous injection of synthetic LG-RH to infantile and sexually mature rats of both sexes induced in the epiphysis the activity of hydroxyindol-O-methyl transpherase (HIOMT), the key enzyme of melatonin synthesis. Increased activity of this enzyme in the epiphysis persisted for at least 5 hours after the administration of LH-RH. HIOMT activation is preceded by a rapid fall (in 5 minutes) of cyclic adenosine-3', 5'-monophosphate in the epiphysis. The data obtained permitted to suppose that feed-back of the hypothalamus with the epiphysis could be realized with the aid of LH-RH.

It has been found that bremazocine predominantly enhances the flexor reflex of the right hind limb, without affecting the left limb. The similarity of the visual data measuring the asymmetry of the pose and the asymmetry of EMG responses to painful stimulation has a high probability. No correlation between the asymmetry of the pose and EMG extensor activity has been found.

Opioid kappa-agonists bremazocine and dynorphin (1-13), sigma-agonist SKF 10.047 and delta-agonist D-Ala2, D-Leu5-enkephalin (DADL) induce postural asymmetry of rats hind limbs under subarachnoidal administration below the level of spinal cord section (T3-T4). The side of the flexed leg depends on the opioid agonist type: bremazocine and dynorphin (1-13) induce predominantly right flexion. SKF 10.047--the left flexion, but not in all doses, DADL--in small doses (1 and 100 pg per animal)--of the right one, in larger doses (up to 10 ng per animal)--of the left one. Saline and opiate mu-agonist morphine do not induce postural asymmetry. Opiate antagonist naloxone prevents asymmetry development when injected prior opioid agonists, and also decreases the number of asymmetries induced by these agonists. Naloxone alone does not influence the per cent of animals with pose asymmetry. The opioid receptors are involved in asymmetry development. The revealed ability of opioid kappa-, delta- and sigma-agonists may be based on lateralization of opioid receptors in the rat spinal cord.

It has been found that bremazocine and met-enkephalin induce postural asymmetry in spinal rats under subarachnoidal and intravenous administration. Intravenous administration of bremazocine to intact animals--even if after it (an hour later) their spinal cord is sectioned--produces no asymmetry, i. e. the spinal cord section is necessary for asymmetry development. The magnitude of postural asymmetry and the side of limb flexion are not constant for each animal, but they change in time. Though, on the average, the percent of asymmetric animals and the ratio of left and right flexions in each group of animals are practically constant. When the spinal cord is sectioned at the T1-T4 level, the bremazocine and metenkephalin induce mainly the right-leg flexion: when the section is made at the T5-T9 level, the left-leg is bent, i. e. the flexion side depends on the level of the section. It is suggested that the ability of opioids to induce postural asymmetry is based on lateralization of opioid receptors in the rat spinal cord.